{
    "clinical_study": {
        "@rank": "117687", 
        "arm_group": {
            "arm_group_label": "Active tratment", 
            "arm_group_type": "Experimental", 
            "description": "Pravastatin, midazolam, losartan, omeprazole, caffeine single dose alone or in combination with PF-05089771"
        }, 
        "brief_summary": {
            "textblock": "This study will test the potential for PF-05089771 to interact with a cocktail of drugs"
        }, 
        "brief_title": "Drug-Drug Interaction Study With PF-05089771", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and/or female subjects between the ages of 18 and 55 years;\n\n          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110\n             lbs);\n\n        Exclusion Criteria:\n\n          -  Any condition possibly affecting drug absorption\n\n          -  History of regular alcohol consumption\n\n          -  Screening supine blood pressure >140 mm Hg (systolic) or >90 mm Hg (diastolic),\n\n          -  Consumption of coffee, cola or other caffeine containing drinks"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "17", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01934569", 
            "org_study_id": "B3291023"
        }, 
        "intervention": {
            "arm_group_label": "Active tratment", 
            "description": "PF-05089771 450mg single dose and titration from 150mg BID to 450mg BID Pravastatin 10mg dingle dose, Midazolam 7.5mg single dose, Losartan 25mg single dose, Caffeine 100mg single dose, Omeprazole 20mg single dose", 
            "intervention_name": "Pravastatin, midazolam, losartan, omeprazole, caffeine and PF-05089771", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Caffeine", 
                "Midazolam", 
                "Omeprazole", 
                "Pravastatin", 
                "Losartan"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 15, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3291023&StudyName=Drug-Drug%20Interaction%20Study%20With%20PF-05089771%20"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Brussels", 
                    "country": "Belgium", 
                    "zip": "B-1070"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation Of The Effect Of PF-05089771 On The Metabolism Of Multiple Cytochrome P450 And OATP1B1 Transporter Substrates", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "24h"
            }, 
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "24h"
            }, 
            {
                "measure": "Minimum Observed Plasma Trough Concentration (Cmin)", 
                "safety_issue": "No", 
                "time_frame": "24h"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "24h"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01934569"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.", 
            "measure": "Change from Baseline in Lipid Parameters", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}